Evidence map›Paper›PMID 42743759›Full record

ArticleRedox biology2026

Combination of genetic eNOS deficiency and high-fat diet induces reproducible cardiometabolic HFpEF.

Mahmoud H Elbatreek, Vinayak Khodade, Darshan Amin, Miguel Huerta, Timothy D Allerton, David J Polhemus, Sanjiv J Shah, Thomas M Vondriska, Traci T Goodchild, David J Lefer

Abstract read
In one paragraph

Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mahmoud H ElbatreekDepartment of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Vinayak KhodadeDepartment of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Darshan AminDepartment of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Miguel HuertaDepartment of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Timothy D AllertonVascular Metabolism Laboratory, Pennington Biomedical Research Center, Baton Rouge, LA, USA.
David J PolhemusDivision of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Sanjiv J ShahNorthwestern University Medicine, Feinberg School of Medicine, Chicago, IL, USA.
Thomas M VondriskaDepartment of Anesthesiology & Perioperative Medicine, Medicine and Physiology, Molecular Biology Institute, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
Traci T GoodchildDepartment of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
David J LeferDepartment of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: David.Lefer@csmc.edu.

Funding

PATHOPHYSIOLOGY OF MYOCARDIAL DISEASEST32HL007227 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Chulan Kwon, WENDY S POST · 1985 to 2026
$21.2M
The role of maternal obesity-driven inflammation and adverse pregnancy outcomes in a mouse model of preeclampsiaP20GM135002 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Jacqueline M Stephens · 2020 to 2026
$18.4M
Hydrogen Sulfide and GLP-1 Combination Therapy to Treat HFpEFR01HL181016 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI DAVID JOSEPH LEFER · 2025 to 2026
$1.5M
Epigenetic Regulation of Heart Failure with Preserved Ejection FractionR01HL174996 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DAVID JOSEPH LEFER, Thomas M. Vondriska · 2025 to 2026
$1.4M
NHLBI NIH HHS R01 HL174996NHLBI NIH HHS R01 HL181016NHLBI NIH HHS T32 HL007227NIGMS NIH HHS P20 GM135002
6 · The paper itself

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a complex, multi-organ cardiometabolic syndrome lacking universally effective therapies. We developed and validated a robust murine model leveraging complete, constitutive genetic endothelial nitric oxide synthase deficiency (eNOS KO) coupled with metabolic stress via a high-fat diet (HFD) in both male and female cohorts. eNOS KO mice subjected to HFD (10 weeks for males; 15 weeks for females) developed a severe and highly reproducible cardiometabolic HFpEF phenotype. Despite preserved left ventricular ejection fraction, both sexes exhibited profound diastolic dysfunction, characterized by elevated E/e' ratios and left ventricular end-diastolic pressures (LVEDP), alongside severe exercise intolerance. Consistent with the systemic clinical syndrome, pathological remodeling extended to multi-organ damage, featuring prominent cardiac fibrosis, severe hepatic steatosis, and renal tubulointerstitial fibrosis. Finally, chronic administration of the dual GIP/GLP-1 receptor agonist tirzepatide largely reversed the hemodynamic, functional, and systemic fibrotic derangements. In conclusion, this novel eNOS KO mouse + HFD model provides a rapidly developing, highly penetrant, and chemically unconfounded platform that ensures robust HFpEF induction across both sexes. This model can be readily adopted for the investigation of mechanistic insights into HFpEF pathobiology and for the study of novel HFpEF therapeutics.

Indexed as

Animal modeleNOSHFpEFHigh-fat dietOrgan fibrosis exercise intoleranceTirzepatide

Identifiers

PMID42743759
PMCPMC13595013

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.